Research & Education
CURE Expert Connections
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Friday Frontline: Cancer Updates, Research and Education on September 13, 2019
From a Hallmark Channel actor revealing a kidney cancer diagnosis to a donor match first-time meeting 20 years later, here’s what is making headlines in the cancer space this week.
Targeted Therapies May Benefit Older Patients With Metastatic Renal Cell Carcinoma
Patients with renal cell carcinoma who were treated with a targeted therapy lived three months longer than people who received older treatments.
Future of Renal Cell Carcinoma: Hope Is on the Horizon
One expert discusses the “extremely interesting and extremely dynamic” field of renal cell carcinoma, and how recent research and FDA actions could offer hope for patients and their doctors.
Collection of Family Cancer History Is Suboptimal, Highlighting Need for Patient Reporting
Kristie L. Kahl
In assessing the quality of family cancer history entered into electronic health records, researchers found that such reporting was suboptimal – highlighting the need to optimize online collection with a provider-free approach.
The Impact of Support Networks & Multidisciplinary Care
The importance of support networks and a multidisciplinary team when managing advanced-stage renal cancer.
Cabozantinib Dose Modification
A discussion regarding the significance of dose modification to mitigate toxicity burden.
Undergoing Treatment: Cabozantinib Toxicity Management
Steven Gallant, a stage 4 renal cell cancer survivor, discusses how he managed the toxicities of cabozantinib frontline therapy.
Frontline Treatment Options for Stage 4 RCC
A discussion regarding the frontline treatment options for aggressive renal cell cancer, and the factors considered in choosing the appropriate therapy.
Advice for Patients with RCC Choosing a Treatment Option
Practical advice for patients during the diagnostic process of renal cell cancer.
The Diagnosis of a Patient with Stage 4 Renal Cell Cancer
Karl J. D’Silva, M.D., and Steven Gallant discuss the process of being diagnosed with stage 4 renal cell cancer.
Not a member?
Sign up now!
Continue without login